<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35545786</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4598</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer</Title>
          <ISOAbbreviation>Mol Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Potential clinical utility of liquid biopsies in ovarian cancer.</ArticleTitle>
        <Pagination>
          <StartPage>114</StartPage>
          <MedlinePgn>114</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">114</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12943-022-01588-8</ELocationID>
        <Abstract>
          <AbstractText>Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. One of the main challenges in the management of OC is the late clinical presentation of disease that results in poor survival. Conventional tissue biopsy methods and serological biomarkers such as CA-125 have limited clinical applications. Liquid biopsy is a novel sampling method that analyzes distinctive tumour components released into the peripheral circulation, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), tumour-educated platelets (TEPs) and exosomes. Increasing evidence suggests that liquid biopsy could enhance the clinical management of OC by improving early diagnosis, predicting prognosis, detecting recurrence, and monitoring response to treatment. Capturing the unique tumour genetic landscape can also guide treatment decisions and the selection of appropriate targeted therapies. Key advantages of liquid biopsy include its non-invasive nature and feasibility, which allow for serial sampling and longitudinal monitoring of dynamic tumour changes over time. In this review, we outline the evidence for the clinical utility of each liquid biopsy component and review the advantages and current limitations of applying liquid biopsy in managing ovarian cancer. We also highlight future directions considering the current challenges and explore areas where more studies are warranted to elucidate its emerging clinical potential.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Jie Wei</ForeName>
            <Initials>JW</Initials>
            <AffiliationInfo>
              <Affiliation>Women's College Research Institute, Women's College Hospital, University of Toronto, 76 Grenville St, Toronto, ON, M5S 1B2, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Charkhchi</LastName>
            <ForeName>Parsa</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Women's College Research Institute, Women's College Hospital, University of Toronto, 76 Grenville St, Toronto, ON, M5S 1B2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akbari</LastName>
            <ForeName>Mohammad R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Women's College Research Institute, Women's College Hospital, University of Toronto, 76 Grenville St, Toronto, ON, M5S 1B2, Canada. mohammad.akbari@utoronto.ca.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. mohammad.akbari@utoronto.ca.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. mohammad.akbari@utoronto.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Cancer</MedlineTA>
        <NlmUniqueID>101147698</NlmUniqueID>
        <ISSNLinking>1476-4598</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074141">Circulating Tumor DNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077216" MajorTopicYN="N">Carcinoma, Ovarian Epithelial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074141" MajorTopicYN="Y">Circulating Tumor DNA</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073890" MajorTopicYN="N">Liquid Biopsy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="Y">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="Y">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declared that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>23</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35545786</ArticleId>
        <ArticleId IdType="pmc">PMC9092780</ArticleId>
        <ArticleId IdType="doi">10.1186/s12943-022-01588-8</ArticleId>
        <ArticleId IdType="pii">10.1186/s12943-022-01588-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451–2460. doi: 10.1002/ijc.30676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.30676</ArticleId>
            <ArticleId IdType="pmc">PMC5595147</ArticleId>
            <ArticleId IdType="pubmed">28257597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J, Soerjomataram I, Dikshit R, et al.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Köbel M, Rahimi K, Rambau PF, et al.  an immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430–441. doi: 10.1097/PGP.0000000000000274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PGP.0000000000000274</ArticleId>
            <ArticleId IdType="pmc">PMC4978603</ArticleId>
            <ArticleId IdType="pubmed">26974996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol. 2011;42(7):918–931. doi: 10.1016/j.humpath.2011.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2011.03.003</ArticleId>
            <ArticleId IdType="pmc">PMC3148026</ArticleId>
            <ArticleId IdType="pubmed">21683865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network  Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615. doi: 10.1038/nature10166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10166</ArticleId>
            <ArticleId IdType="pmc">PMC3163504</ArticleId>
            <ArticleId IdType="pubmed">21720365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>González-Martín A, Pothuri B, Vergote I, et al.  Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402. doi: 10.1056/NEJMoa1910962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910962</ArticleId>
            <ArticleId IdType="pubmed">31562799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JF, Matulonis UA. What Is the place of PARP Inhibitors in ovarian cancer treatment? Curr Oncol Rep. 2016;18(5):29. doi: 10.1007/s11912-016-0515-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11912-016-0515-z</ArticleId>
            <ArticleId IdType="pubmed">26984416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirza MR, Monk BJ, Herrstedt J, et al.  niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164. doi: 10.1056/NEJMoa1611310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1611310</ArticleId>
            <ArticleId IdType="pubmed">27717299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374(9698):1371–1382. doi: 10.1016/S0140-6736(09)61338-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)61338-6</ArticleId>
            <ArticleId IdType="pubmed">19793610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavone MB, Herzog TJ, Lewin SN, et al.  Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205(5):480.e1–8. doi: 10.1016/j.ajog.2011.06.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajog.2011.06.049</ArticleId>
            <ArticleId IdType="pubmed">21861962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan RJ, Armstrong DK, Alvarez RD, et al.  Ovarian Cancer, Version 1 2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(9):1134–1163. doi: 10.6004/jnccn.2016.0122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2016.0122</ArticleId>
            <ArticleId IdType="pubmed">27587625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2018;143(Suppl 2):59–78. doi: 10.1002/ijgo.12614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijgo.12614</ArticleId>
            <ArticleId IdType="pubmed">30306591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs IJ, Menon U, Ryan A, et al.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–956. doi: 10.1016/S0140-6736(15)01224-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)01224-6</ArticleId>
            <ArticleId IdType="pmc">PMC4779792</ArticleId>
            <ArticleId IdType="pubmed">26707054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Ma J, Jin Y, et al.  Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition. Sci Rep. 2021;11(1):6540. doi: 10.1038/s41598-021-86122-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-86122-4</ArticleId>
            <ArticleId IdType="pmc">PMC7985206</ArticleId>
            <ArticleId IdType="pubmed">33753862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013;131(2):352–356. doi: 10.1016/j.ygyno.2013.08.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2013.08.006</ArticleId>
            <ArticleId IdType="pubmed">23954902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhlmann JD, Wimberger P, Bankfalvi A, et al.  ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem. 2014;60(10):1282–1289. doi: 10.1373/clinchem.2014.224808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2014.224808</ArticleId>
            <ArticleId IdType="pubmed">25015375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie L, Li F, Huang X, et al.  Folic Acid Targeting for Efficient Isolation and Detection of Ovarian Cancer CTCs from Human Whole Blood Based on Two-Step Binding Strategy. ACS Appl Mater Interfaces. 2018;10(16):14055–14062. doi: 10.1021/acsami.8b02583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.8b02583</ArticleId>
            <ArticleId IdType="pubmed">29620849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marth C, Kisic J, Kaern J, Tropé C, Fodstad Ø. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer. 2002;94(3):707–712. doi: 10.1002/cncr.10250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.10250</ArticleId>
            <ArticleId IdType="pubmed">11857303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaborowski MP, Stefens-Stawna P, Osztynowicz K, et al.  Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy. Cancer Immunol Immunother. 2021;70(5):1277–1289. doi: 10.1007/s00262-020-02750-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-020-02750-1</ArticleId>
            <ArticleId IdType="pmc">PMC8053162</ArticleId>
            <ArticleId IdType="pubmed">33136178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obermayr E, Reiner A, Brandt B, et al.  The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium. Cancers (Basel) 2021;13(11):2613. doi: 10.3390/cancers13112613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13112613</ArticleId>
            <ArticleId IdType="pmc">PMC8198007</ArticleId>
            <ArticleId IdType="pubmed">34073412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obermayr E, Castillo-Tong DC, Pils D, et al.  Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – a study of the OVCAD consortium. Gynecol Oncol. 2013;128(1):15–21. doi: 10.1016/j.ygyno.2012.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2012.09.021</ArticleId>
            <ArticleId IdType="pubmed">23017820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolostova K, Pinkas M, Jakabova A, et al.  Molecular characterization of circulating tumor cells in ovarian cancer. Am J Cancer Res. 2016;6(5):973–980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4889713</ArticleId>
            <ArticleId IdType="pubmed">27293992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obermayr E, Sanchez-Cabo F, Tea MKM, et al.  Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010;10:666. doi: 10.1186/1471-2407-10-666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-10-666</ArticleId>
            <ArticleId IdType="pmc">PMC3013085</ArticleId>
            <ArticleId IdType="pubmed">21129172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ried K, Eng P, Sali A. Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study. Asian Pac J Cancer Prev. 2017;18(8):2275–2285. doi: 10.22034/APJCP.2017.18.8.2275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.22034/APJCP.2017.18.8.2275</ArticleId>
            <ArticleId IdType="pmc">PMC5697492</ArticleId>
            <ArticleId IdType="pubmed">28843267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim M, Suh DH, Choi JY, et al.  Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: A prospective observational study. Medicine (Baltimore) 2019;98(20):e15354. doi: 10.1097/MD.0000000000015354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000015354</ArticleId>
            <ArticleId IdType="pmc">PMC6531062</ArticleId>
            <ArticleId IdType="pubmed">31096435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao Q, Zhang Q, Zheng C, et al.  Detection of circulating tumour cells in patients with epithelial ovarian cancer by a microfluidic system. Int J Clin Exp Pathol. 2017;10(9):9599–9606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6965958</ArticleId>
            <ArticleId IdType="pubmed">31966837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obermayr E, Maritschnegg E, Agreiter C, et al.  Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. Oncotarget. 2018;9(1):812–823. doi: 10.18632/oncotarget.22549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.22549</ArticleId>
            <ArticleId IdType="pmc">PMC5787513</ArticleId>
            <ArticleId IdType="pubmed">29416657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee M, Kim EJ, Cho Y, et al.  Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. Gynecol Oncol. 2017;145(2):361–365. doi: 10.1016/j.ygyno.2017.02.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2017.02.042</ArticleId>
            <ArticleId IdType="pubmed">28274569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol. 2009;112(1):185–191. doi: 10.1016/j.ygyno.2008.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2008.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC2606929</ArticleId>
            <ArticleId IdType="pubmed">18954898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishima Y, Paiva B, Shi J, et al.  The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017;19(1):218–224. doi: 10.1016/j.celrep.2017.03.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.03.025</ArticleId>
            <ArticleId IdType="pmc">PMC5439509</ArticleId>
            <ArticleId IdType="pubmed">28380360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118(3):277–279. doi: 10.1016/j.cell.2004.07.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2004.07.011</ArticleId>
            <ArticleId IdType="pubmed">15294153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhim AD, Mirek ET, Aiello NM, et al.  EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–361. doi: 10.1016/j.cell.2011.11.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.11.025</ArticleId>
            <ArticleId IdType="pmc">PMC3266542</ArticleId>
            <ArticleId IdType="pubmed">22265420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim MY, Oskarsson T, Acharyya S, et al.  Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–1326. doi: 10.1016/j.cell.2009.11.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.11.025</ArticleId>
            <ArticleId IdType="pmc">PMC2810531</ArticleId>
            <ArticleId IdType="pubmed">20064377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young R, Pailler E, Billiot F, et al.  Circulating tumor cells in lung cancer. Acta Cytol. 2012;56(6):655–660. doi: 10.1159/000345182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000345182</ArticleId>
            <ArticleId IdType="pubmed">23207444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011;192(3):373–382. doi: 10.1083/jcb.201010021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201010021</ArticleId>
            <ArticleId IdType="pmc">PMC3101098</ArticleId>
            <ArticleId IdType="pubmed">21300848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson NJ. Circulating tumor cells: will they be clinically useful? J Natl Cancer Inst. 2010;102(3):146–148. doi: 10.1093/jnci/djq016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djq016</ArticleId>
            <ArticleId IdType="pubmed">20107163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alix-Panabières C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016;6(5):479–491. doi: 10.1158/2159-8290.CD-15-1483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-15-1483</ArticleId>
            <ArticleId IdType="pubmed">26969689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fidler IJ. Cancer biology is the foundation for therapy. Cancer Biol Ther. 2005;4(9):1036–1039. doi: 10.4161/cbt.4.9.2111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cbt.4.9.2111</ArticleId>
            <ArticleId IdType="pubmed">16222123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–284. doi: 10.1038/nrc2622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2622</ArticleId>
            <ArticleId IdType="pubmed">19308067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3239</ArticleId>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong X, Zhang H, Zhu Y, et al.  Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. Mol Cancer. 2020;19(1):15. doi: 10.1186/s12943-020-1141-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-020-1141-9</ArticleId>
            <ArticleId IdType="pmc">PMC6982393</ArticleId>
            <ArticleId IdType="pubmed">31980023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaiswal S, Jamieson CHM, Pang WW, et al.  CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285. doi: 10.1016/j.cell.2009.05.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.05.046</ArticleId>
            <ArticleId IdType="pmc">PMC2775564</ArticleId>
            <ArticleId IdType="pubmed">19632178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agerbæk MØ, Bang-Christensen SR, Yang MH, et al.  The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nat Commun. 2018;9(1):3279. doi: 10.1038/s41467-018-05793-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-05793-2</ArticleId>
            <ArticleId IdType="pmc">PMC6095877</ArticleId>
            <ArticleId IdType="pubmed">30115931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asante DB, Calapre L, Ziman M, Meniawy TM, Gray ES. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? Cancer Lett. 2020;468:59–71. doi: 10.1016/j.canlet.2019.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2019.10.014</ArticleId>
            <ArticleId IdType="pubmed">31610267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JH, Chung HH, Jeong MS, Song MR, Kang KW, Kim JS. One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles. Int J Nanomedicine. 2013;8:2247–2257. doi: 10.2147/IJN.S45059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S45059</ArticleId>
            <ArticleId IdType="pmc">PMC3693817</ArticleId>
            <ArticleId IdType="pubmed">23818781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–484. doi: 10.1038/nrclinonc.2013.110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2013.110</ArticleId>
            <ArticleId IdType="pubmed">23836314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–548. doi: 10.1038/nrclinonc.2017.14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.14</ArticleId>
            <ArticleId IdType="pubmed">28252003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo YM, Patel P, Wainscoat JS, Sampietro M, Gillmer MD, Fleming KA. Prenatal sex determination by DNA amplification from maternal peripheral blood. Lancet. 1989;2(8676):1363–1365. doi: 10.1016/s0140-6736(89)91969-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(89)91969-7</ArticleId>
            <ArticleId IdType="pubmed">2574306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650–661. doi: 10.1158/2159-8290.CD-13-1014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-1014</ArticleId>
            <ArticleId IdType="pmc">PMC4433544</ArticleId>
            <ArticleId IdType="pubmed">24801577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diehl F, Li M, Dressman D, et al.  Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368–16373. doi: 10.1073/pnas.0507904102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0507904102</ArticleId>
            <ArticleId IdType="pmc">PMC1283450</ArticleId>
            <ArticleId IdType="pubmed">16258065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahr S, Hentze H, Englisch S, et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11245480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin Biol Ther. 2012;12(Suppl 1):S209–215. doi: 10.1517/14712598.2012.688023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14712598.2012.688023</ArticleId>
            <ArticleId IdType="pubmed">22594497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mari R, Mamessier E, Lambaudie E, et al.  Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. Cancers (Basel) 2019;11(6):E774. doi: 10.3390/cancers11060774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11060774</ArticleId>
            <ArticleId IdType="pmc">PMC6627130</ArticleId>
            <ArticleId IdType="pubmed">31167492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbosa A, Peixoto A, Pinto P, Pinheiro M, Teixeira MR. Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. Expert Rev Mol Med. 2018;20:e6. doi: 10.1017/erm.2018.5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/erm.2018.5</ArticleId>
            <ArticleId IdType="pubmed">30558693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, Pu K, Ge L, Wu X. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis. Gene. 2019;714:143993. doi: 10.1016/j.gene.2019.143993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2019.143993</ArticleId>
            <ArticleId IdType="pubmed">31330238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvi S, Gurioli G, De Giorgi U, et al.  Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther. 2016;9:6549–6559. doi: 10.2147/OTT.S100901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S100901</ArticleId>
            <ArticleId IdType="pmc">PMC5087772</ArticleId>
            <ArticleId IdType="pubmed">27822059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swisher EM, Wollan M, Mahtani SM, et al.  Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol. 2005;193(3 Pt 1):662–667. doi: 10.1016/j.ajog.2005.01.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajog.2005.01.054</ArticleId>
            <ArticleId IdType="pubmed">16150257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016;164(1–2):57–68. doi: 10.1016/j.cell.2015.11.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.11.050</ArticleId>
            <ArticleId IdType="pmc">PMC4715266</ArticleId>
            <ArticleId IdType="pubmed">26771485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang R, Nakahira K, Guo X, Choi AMK, Gu Z. Very Short Mitochondrial DNA Fragments and Heteroplasmy in Human Plasma. Sci Rep. 2016;6:36097. doi: 10.1038/srep36097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep36097</ArticleId>
            <ArticleId IdType="pmc">PMC5095883</ArticleId>
            <ArticleId IdType="pubmed">27811968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mouliere F, Chandrananda D, Piskorz AM, et al.  Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921. doi: 10.1126/scitranslmed.aat4921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aat4921</ArticleId>
            <ArticleId IdType="pmc">PMC6483061</ArticleId>
            <ArticleId IdType="pubmed">30404863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987;23(6):707–712. doi: 10.1016/0277-5379(87)90266-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0277-5379(87)90266-5</ArticleId>
            <ArticleId IdType="pubmed">3653190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang P, Chan CWM, Chan KCA, et al.  Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015;112(11):E1317–1325. doi: 10.1073/pnas.1500076112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1500076112</ArticleId>
            <ArticleId IdType="pmc">PMC4372002</ArticleId>
            <ArticleId IdType="pubmed">25646427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muhanna N, Di Grappa MA, Chan HHL, et al.  Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer. Sci Rep. 2017;7(1):16723. doi: 10.1038/s41598-017-17079-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-17079-6</ArticleId>
            <ArticleId IdType="pmc">PMC5711859</ArticleId>
            <ArticleId IdType="pubmed">29196748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beyer C, Stearns NA, Giessl A, Distler JHW, Schett G, Pisetsky DS. The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death. Innate Immun. 2012;18(5):727–737. doi: 10.1177/1753425912437981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1753425912437981</ArticleId>
            <ArticleId IdType="pmc">PMC3724467</ArticleId>
            <ArticleId IdType="pubmed">22344226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beyer C, Pisetsky DS. Modeling nuclear molecule release during in vitro cell death. Autoimmunity. 2013;46(5):298–301. doi: 10.3109/08916934.2012.750297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08916934.2012.750297</ArticleId>
            <ArticleId IdType="pubmed">23244202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng C, Omura-Minamisawa M, Kang Y, Hara T, Koike I, Inoue T. Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci. 2009;100(2):303–309. doi: 10.1111/j.1349-7006.2008.01021.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2008.01021.x</ArticleId>
            <ArticleId IdType="pubmed">19200259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">837366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35(3):347–376. doi: 10.1007/s10555-016-9629-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-016-9629-x</ArticleId>
            <ArticleId IdType="pmc">PMC5035665</ArticleId>
            <ArticleId IdType="pubmed">27392603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronkhorst AJ, Wentzel JF, Aucamp J, van Dyk E, du Plessis L, Pretorius PJ. Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta. 2016;1863(1):157–165. doi: 10.1016/j.bbamcr.2015.10.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2015.10.022</ArticleId>
            <ArticleId IdType="pubmed">26529550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S, Coldren C, Karunamurthy A, et al.  Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the association for molecular pathology and the College of American Pathologists. J Mol Diagn. 2018;20(1):4–27. doi: 10.1016/j.jmoldx.2017.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jmoldx.2017.11.003</ArticleId>
            <ArticleId IdType="pubmed">29154853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev. 2011;243(1):206–214. doi: 10.1111/j.1600-065X.2011.01044.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-065X.2011.01044.x</ArticleId>
            <ArticleId IdType="pmc">PMC3609431</ArticleId>
            <ArticleId IdType="pubmed">21884178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemp MG, Reardon JT, Lindsey-Boltz LA, Sancar A. Mechanism of release and fate of excised oligonucleotides during nucleotide excision repair. J Biol Chem. 2012;287(27):22889–22899. doi: 10.1074/jbc.M112.374447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.374447</ArticleId>
            <ArticleId IdType="pmc">PMC3391136</ArticleId>
            <ArticleId IdType="pubmed">22573372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters DL, Pretorius PJ. Origin, translocation and destination of extracellular occurring DNA–a new paradigm in genetic behaviour. Clin Chim Acta. 2011;412(11–12):806–811. doi: 10.1016/j.cca.2011.01.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cca.2011.01.026</ArticleId>
            <ArticleId IdType="pubmed">21277292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Underhill HR, Kitzman JO, Hellwig S, et al.  Fragment Length of Circulating Tumor DNA. PLoS Genet. 2016;12(7):e1006162. doi: 10.1371/journal.pgen.1006162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1006162</ArticleId>
            <ArticleId IdType="pmc">PMC4948782</ArticleId>
            <ArticleId IdType="pubmed">27428049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mouliere F, Piskorz AM, Chandrananda D, Moore E, Morris J, Smith CG, et al. Selecting short DNA fragments in plasma improves detection of circulating tumour DNA. bioRxiv. 2017;134437. 10.1101/134437.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang A, Zhang X, Zhou SL, et al.  Plasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma. J Cancer. 2016;7(13):1798–1803. doi: 10.7150/jca.15618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.15618</ArticleId>
            <ArticleId IdType="pmc">PMC5039362</ArticleId>
            <ArticleId IdType="pubmed">27698918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Sun L-yu, Zheng H qun, Zhang Q fan, Jin X ming. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathology. 2012;44(4):318–324. doi: 10.1097/PAT.0b013e328353a24c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAT.0b013e328353a24c</ArticleId>
            <ArticleId IdType="pubmed">28193336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gang F, Guorong L, An Z, Anne GP, Christian G, Jacques T. Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. Urology. 2010;75(2):262–265. doi: 10.1016/j.urology.2009.06.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.urology.2009.06.048</ArticleId>
            <ArticleId IdType="pubmed">19962739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini M, Pucciarelli S, Enzo MV, et al.  Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol. 2011;18(9):2461–2468. doi: 10.1245/s10434-011-1638-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1245/s10434-011-1638-y</ArticleId>
            <ArticleId IdType="pubmed">21416156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung F, Kulasingam V, Diamandis EP, et al.  Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction? Clin Chem. 2016;62(8):1054–1060. doi: 10.1373/clinchem.2016.260331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2016.260331</ArticleId>
            <ArticleId IdType="pmc">PMC5326709</ArticleId>
            <ArticleId IdType="pubmed">27259816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stephan F, Marsman G, Bakker LM, et al.  Cooperation of factor VII-activating protease and serum DNase I in the release of nucleosomes from necrotic cells. Arthritis Rheumatol. 2014;66(3):686–693. doi: 10.1002/art.38265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.38265</ArticleId>
            <ArticleId IdType="pubmed">24574229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin M, Leffler J, Smoląg KI, et al.  Factor H uptake regulates intracellular C3 activation during apoptosis and decreases the inflammatory potential of nucleosomes. Cell Death Differ. 2016;23(5):903–911. doi: 10.1038/cdd.2015.164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.164</ArticleId>
            <ArticleId IdType="pmc">PMC4832108</ArticleId>
            <ArticleId IdType="pubmed">26768663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999;64(1):218–224. doi: 10.1086/302205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/302205</ArticleId>
            <ArticleId IdType="pmc">PMC1377720</ArticleId>
            <ArticleId IdType="pubmed">9915961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thierry AR, Mouliere F, Gongora C, et al.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010;38(18):6159–6175. doi: 10.1093/nar/gkq421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkq421</ArticleId>
            <ArticleId IdType="pmc">PMC2952865</ArticleId>
            <ArticleId IdType="pubmed">20494973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García Moreira V, de la Cera MT, Gago González E, Prieto García B, Alvarez Menéndez FV. Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR. Clin Chem Lab Med. 2006;44(12):1410–1415. doi: 10.1515/CCLM.2006.252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1515/CCLM.2006.252</ArticleId>
            <ArticleId IdType="pubmed">17163815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gauthier VJ, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice. J Immunol. 1996;156(3):1151–1156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8557992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu SCY, Lee SWY, Jiang P, et al.  High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin Chem. 2013;59(8):1228–1237. doi: 10.1373/clinchem.2013.203679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2013.203679</ArticleId>
            <ArticleId IdType="pubmed">23603797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phallen J, Sausen M, Adleff V, et al.  Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415. doi: 10.1126/scitranslmed.aan2415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aan2415</ArticleId>
            <ArticleId IdType="pmc">PMC6714979</ArticleId>
            <ArticleId IdType="pubmed">28814544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bettegowda C, Sausen M, Leary RJ, et al.  Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3007094</ArticleId>
            <ArticleId IdType="pmc">PMC4017867</ArticleId>
            <ArticleId IdType="pubmed">24553385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piskorz A, Lin KK, Morris JA, et al.  Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial. J Clin Oncol. 2016;34(15):5549–5549. doi: 10.1200/JCO.2016.34.15_suppl.5549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.34.15_suppl.5549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Žilovič D, Čiurlienė R, Sabaliauskaitė R, Jarmalaitė S. Future Screening Prospects for Ovarian Cancer. Cancers (Basel) 2021;13(15):3840. doi: 10.3390/cancers13153840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13153840</ArticleId>
            <ArticleId IdType="pmc">PMC8345180</ArticleId>
            <ArticleId IdType="pubmed">34359740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitt MW, Fox EJ, Prindle MJ, et al.  Sequencing small genomic targets with high efficiency and extreme accuracy. Nat Methods. 2015;12(5):423–425. doi: 10.1038/nmeth.3351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.3351</ArticleId>
            <ArticleId IdType="pmc">PMC4414912</ArticleId>
            <ArticleId IdType="pubmed">25849638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn EH, Hirohata K, Kohrn BF, Fox EJ, Chang CC, Loeb LA. Detection of Ultra-Rare Mitochondrial Mutations in Breast Stem Cells by Duplex Sequencing. PLoS ONE. 2015;10(8):e0136216. doi: 10.1371/journal.pone.0136216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0136216</ArticleId>
            <ArticleId IdType="pmc">PMC4549069</ArticleId>
            <ArticleId IdType="pubmed">26305705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinde I, Bettegowda C, Wang Y, et al.  Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167ra4. doi: 10.1126/scitranslmed.3004952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3004952</ArticleId>
            <ArticleId IdType="pmc">PMC3757513</ArticleId>
            <ArticleId IdType="pubmed">23303603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Li L, Douville C, et al.  Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018;10(433):eaap8793. doi: 10.1126/scitranslmed.aap8793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aap8793</ArticleId>
            <ArticleId IdType="pmc">PMC6320220</ArticleId>
            <ArticleId IdType="pubmed">29563323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maritschnegg E, Wang Y, Pecha N, et al.  Lavage of the uterine cavity for molecular detection of müllerian duct carcinomas: a proof-of-concept study. J Clin Oncol. 2015;33(36):4293–4300. doi: 10.1200/JCO.2015.61.3083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.61.3083</ArticleId>
            <ArticleId IdType="pmc">PMC4678180</ArticleId>
            <ArticleId IdType="pubmed">26552420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erickson BK, Kinde I, Dobbin ZC, et al.  Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol. 2014;124(5):881–885. doi: 10.1097/AOG.0000000000000484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/AOG.0000000000000484</ArticleId>
            <ArticleId IdType="pmc">PMC4316672</ArticleId>
            <ArticleId IdType="pubmed">25437714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naz S, Hashmi AA, Ali R, et al.  Role of peritoneal washing cytology in ovarian malignancies: correlation with histopathological parameters. World J Surg Oncol. 2015;13:315. doi: 10.1186/s12957-015-0732-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-015-0732-1</ArticleId>
            <ArticleId IdType="pmc">PMC4641365</ArticleId>
            <ArticleId IdType="pubmed">26556439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuna RE, Behrens A. Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. J Natl Cancer Inst. 1996;88(14):980–987. doi: 10.1093/jnci/88.14.980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/88.14.980</ArticleId>
            <ArticleId IdType="pubmed">8667429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia MM, Deng J, Cheng XL, et al.  Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. Oncotarget. 2017;8(6):9660–9671. doi: 10.18632/oncotarget.14173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.14173</ArticleId>
            <ArticleId IdType="pmc">PMC5354761</ArticleId>
            <ArticleId IdType="pubmed">28039447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anker P, Lyautey J, Lederrey C, Stroun M. Circulating nucleic acids in plasma or serum. Clin Chim Acta. 2001;313(1–2):143–146. doi: 10.1016/s0009-8981(01)00666-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0009-8981(01)00666-0</ArticleId>
            <ArticleId IdType="pubmed">11694252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dwivedi SKD, Rao G, Dey A, Mukherjee P, Wren JD, Bhattacharya R. Small Non-Coding-RNA in Gynecological Malignancies. Cancers (Basel) 2021;13(5):1085. doi: 10.3390/cancers13051085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13051085</ArticleId>
            <ArticleId IdType="pmc">PMC7961667</ArticleId>
            <ArticleId IdType="pubmed">33802524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999;5(8):1961–1965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10473072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mateescu B, Batista L, Cardon M, et al.  miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011;17(12):1627–1635. doi: 10.1038/nm.2512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.2512</ArticleId>
            <ArticleId IdType="pubmed">22101765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen W, Song M, Liu J, et al.  MiR-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS ONE. 2014;9(1):e86871. doi: 10.1371/journal.pone.0086871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0086871</ArticleId>
            <ArticleId IdType="pmc">PMC3899311</ArticleId>
            <ArticleId IdType="pubmed">24466274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N, Yang L, Wang H, et al.  MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. PLoS ONE. 2015;10(6):e0128886. doi: 10.1371/journal.pone.0128886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0128886</ArticleId>
            <ArticleId IdType="pmc">PMC4456206</ArticleId>
            <ArticleId IdType="pubmed">26043084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Zhao F, Xiao Z, Yao L. Exosomal microRNA-205 is involved in proliferation, migration, invasion, and apoptosis of ovarian cancer cells via regulating VEGFA. Cancer Cell Int. 2019;19:281. doi: 10.1186/s12935-019-0990-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-019-0990-z</ArticleId>
            <ArticleId IdType="pmc">PMC6836480</ArticleId>
            <ArticleId IdType="pubmed">31719795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13–21. doi: 10.1016/j.ygyno.2008.04.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2008.04.033</ArticleId>
            <ArticleId IdType="pubmed">18589210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao YC, Wu J. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. Tumour Biol. 2015;36(6):4843–4850. doi: 10.1007/s13277-015-3138-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-015-3138-3</ArticleId>
            <ArticleId IdType="pubmed">25636451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7(13):16923–16935. doi: 10.18632/oncotarget.7850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7850</ArticleId>
            <ArticleId IdType="pmc">PMC4941360</ArticleId>
            <ArticleId IdType="pubmed">26943577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Choi MC, Jeong JY, et al.  Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas. J Cancer. 2019;10(9):1958–1967. doi: 10.7150/jca.30231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.30231</ArticleId>
            <ArticleId IdType="pmc">PMC6548168</ArticleId>
            <ArticleId IdType="pubmed">31205555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuzaki J, Ochiya T. Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. Int J Clin Oncol. 2017;22(3):413–420. doi: 10.1007/s10147-017-1104-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10147-017-1104-3</ArticleId>
            <ArticleId IdType="pubmed">28243946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elias KM, Fendler W, Stawiski K, et al.  Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. Elife. 2017;6:e28932. doi: 10.7554/eLife.28932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.28932</ArticleId>
            <ArticleId IdType="pmc">PMC5679755</ArticleId>
            <ArticleId IdType="pubmed">29087294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokoi A, Yoshioka Y, Hirakawa A, et al.  A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017;8(52):89811–89823. doi: 10.18632/oncotarget.20688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.20688</ArticleId>
            <ArticleId IdType="pmc">PMC5685711</ArticleId>
            <ArticleId IdType="pubmed">29163790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokoi A, Matsuzaki J, Yamamoto Y, et al.  Integrated extracellular microRNA profiling for ovarian cancer screening. Nat Commun. 2018;9(1):4319. doi: 10.1038/s41467-018-06434-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-06434-4</ArticleId>
            <ArticleId IdType="pmc">PMC6192980</ArticleId>
            <ArticleId IdType="pubmed">30333487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–157. doi: 10.1261/rna.035667.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1261/rna.035667.112</ArticleId>
            <ArticleId IdType="pmc">PMC3543092</ArticleId>
            <ArticleId IdType="pubmed">23249747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA. 2014;20(12):1829–1842. doi: 10.1261/rna.047126.114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1261/rna.047126.114</ArticleId>
            <ArticleId IdType="pmc">PMC4238349</ArticleId>
            <ArticleId IdType="pubmed">25404635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nature Biotechnol. 2014;32(5):453–461. doi: 10.1038/nbt.2890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.2890</ArticleId>
            <ArticleId IdType="pmc">PMC4121655</ArticleId>
            <ArticleId IdType="pubmed">24811520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed I, Karedath T, Andrews SS, et al.  Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma. Oncotarget. 2016;7(24):36322–36381. doi: 10.18632/oncotarget.8917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Zhu Y, Zhang W, Lang J, Ning L. Utility of plasma circBNC2 as a diagnostic biomarker in epithelial ovarian cancer. Onco Targets Ther. 2019;12:9715–9723. doi: 10.2147/OTT.S211413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S211413</ArticleId>
            <ArticleId IdType="pmc">PMC6859958</ArticleId>
            <ArticleId IdType="pubmed">32009804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meryet-Figui`ere M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L, Denoyelle C. An overview of long non-coding RNAs in ovarian cancers. Oncotarget. 2016;7:44719–44734. doi: 10.18632/oncotarget.8089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8089</ArticleId>
            <ArticleId IdType="pmc">PMC5190131</ArticleId>
            <ArticleId IdType="pubmed">26992233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X, Feng Y, Zhang D, et al.  A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Canc Cell. 2014;26:344–357. doi: 10.1016/j.ccr.2014.07.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2014.07.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao L, Ji G, Le X, Wang C, et al.  Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Canc. Res. 2017;77:1369–1382. doi: 10.1158/0008-5472.CAN-16-1615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-1615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Leng T, Zhang Q, Zhao Q, Nie X, Yang L. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway. Biomed Pharmacother. 2018;102:302–308. doi: 10.1016/j.biopha.2018.03.071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.03.071</ArticleId>
            <ArticleId IdType="pubmed">29571014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shang A, Wang W, Gu C, Chen C, Zeng B, Yang Y, Ji P, Sun J, Wu J, Lu W, Sun Z, Li D. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. J. Exp. Clin. Cancer Res. 2019;38:411. doi: 10.1186/s13046-019-1394-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1394-6</ArticleId>
            <ArticleId IdType="pmc">PMC6751824</ArticleId>
            <ArticleId IdType="pubmed">31533774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK. The long noncoding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 2019;58:196–205. doi: 10.1002/mc.22919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.22919</ArticleId>
            <ArticleId IdType="pubmed">30294913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu SP, Yang JX, Cao DY, Shen K. Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials, Cancer. Biol Med. 2013;10:138–141. doi: 10.7497/j.issn.2095-3941.2013.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7497/j.issn.2095-3941.2013.03.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu E, Liu Z, Zhou Y. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol. 2015;8:3803–3810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4466949</ArticleId>
            <ArticleId IdType="pubmed">26097562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Worku T, Bhattarai D, Ayers D, Wang K, Wang C, Rehman ZU, Talpur HS, Yang L. Long non-coding RNAs: the new horizon of gene regulation in ovarian cancer. Cell Physiol Biochem. 2017;44:948–966. doi: 10.1159/000485395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000485395</ArticleId>
            <ArticleId IdType="pubmed">29179183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klement GL, Yip TT, Cassiola F, et al.  Platelets actively sequester angiogenesis regulators. Blood. 2009;113(12):2835–2842. doi: 10.1182/blood-2008-06-159541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2008-06-159541</ArticleId>
            <ArticleId IdType="pmc">PMC2661866</ArticleId>
            <ArticleId IdType="pubmed">19036702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuznetsov HS, Marsh T, Markens BA, et al.  Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov. 2012;2(12):1150–1165. doi: 10.1158/2159-8290.CD-12-0216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-12-0216</ArticleId>
            <ArticleId IdType="pmc">PMC3517696</ArticleId>
            <ArticleId IdType="pubmed">22896036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Power KA, McRedmond JP, de Stefani A, Gallagher WM, Gaora PO. High-throughput proteomics detection of novel splice isoforms in human platelets. PLoS ONE. 2009;4(3):e5001. doi: 10.1371/journal.pone.0005001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0005001</ArticleId>
            <ArticleId IdType="pmc">PMC2654914</ArticleId>
            <ArticleId IdType="pubmed">19308253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowley JW, Oler AJ, Tolley ND, et al.  Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. 2011;118(14):e101–111. doi: 10.1182/blood-2011-03-339705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-03-339705</ArticleId>
            <ArticleId IdType="pmc">PMC3193274</ArticleId>
            <ArticleId IdType="pubmed">21596849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Best MG, Sol N, Kooi I, et al.  RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell. 2015;28(5):666–676. doi: 10.1016/j.ccell.2015.09.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.09.018</ArticleId>
            <ArticleId IdType="pmc">PMC4644263</ArticleId>
            <ArticleId IdType="pubmed">26525104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piek J, In ’t Veld S, Best M, et al. EP457 Assessment of ovarian tumors with tumor educated platelets (TEPs). Int J Gynecol Cancer. 2019;29(Suppl 4):A291. 10.1136/ijgc-2019-ESGO.516.</Citation>
        </Reference>
        <Reference>
          <Citation>Piek JMJ. Early Detection of Ovarian Cancer and Treatment Response by Tumor Educated Platelets (TEP’s) and Circulating Tumor DNA (CtDNA). ClinicalTrials.gov Identifier: NCT04022863. 2019-2023. https://clinicaltrials.gov/ct2/show/NCT04022863.</Citation>
        </Reference>
        <Reference>
          <Citation>Giannakeas V, Narod SA. Incidence of Cancer Among Adults With Thrombocytosis in Ontario, Canada. JAMA Netw Open. 2021;4(8):e2120633. doi: 10.1001/jamanetworkopen.2021.20633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2021.20633</ArticleId>
            <ArticleId IdType="pubmed">34383058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen J, Zhu X, Fei J, Shi P, Yu S, Zhou J. Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect. Onco Targets Ther. 2018;11:2831–2841. doi: 10.2147/OTT.S159829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S159829</ArticleId>
            <ArticleId IdType="pmc">PMC5961474</ArticleId>
            <ArticleId IdType="pubmed">29844681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melo SA, Sugimoto H, O’Connell JT, et al.  Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–721. doi: 10.1016/j.ccell.2014.09.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2014.09.005</ArticleId>
            <ArticleId IdType="pmc">PMC4254633</ArticleId>
            <ArticleId IdType="pubmed">25446899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye SB, Li ZL, Luo DH, et al.  Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014;5(14):5439–5452. doi: 10.18632/oncotarget.2118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2118</ArticleId>
            <ArticleId IdType="pmc">PMC4170615</ArticleId>
            <ArticleId IdType="pubmed">24978137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Au Yeung CL, Co NN, Tsuruga T, et al.  Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150. doi: 10.1038/ncomms11150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms11150</ArticleId>
            <ArticleId IdType="pmc">PMC4820618</ArticleId>
            <ArticleId IdType="pubmed">27021436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng W, Dean DC, Hornicek FJ, Shi H, Duan Z. Exosomes promote pre-metastatic niche formation in ovarian cancer. Mol Cancer. 2019;18(1):124. doi: 10.1186/s12943-019-1049-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-019-1049-4</ArticleId>
            <ArticleId IdType="pmc">PMC6691526</ArticleId>
            <ArticleId IdType="pubmed">31409361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lobb RJ, Lima LG, Möller A. Exosomes: Key mediators of metastasis and pre-metastatic niche formation. Semin Cell Dev Biol. 2017;67:3–10. doi: 10.1016/j.semcdb.2017.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcdb.2017.01.004</ArticleId>
            <ArticleId IdType="pubmed">28077297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivoltini L, Chiodoni C, Squarcina P, et al.  TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor Site. Clin Cancer Res. 2016;22(14):3499–3512. doi: 10.1158/1078-0432.CCR-15-2170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-2170</ArticleId>
            <ArticleId IdType="pubmed">26944067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gobbo J, Marcion G, Cordonnier M, et al. Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. J Natl Cancer Inst. 20156;108(3):djv330. 10.1093/jnci/djv330.</Citation>
        </Reference>
        <Reference>
          <Citation>Szajnik M, Derbis M, Lach M, et al. Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. Gynecol Obstet (Sunnyvale). 2013;Suppl 4:3. 10.4172/2161-0932.S4-003.</Citation>
        </Reference>
        <Reference>
          <Citation>Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 2009;9:244. doi: 10.1186/1471-2407-9-244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-9-244</ArticleId>
            <ArticleId IdType="pmc">PMC2719664</ArticleId>
            <ArticleId IdType="pubmed">19619303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Runz S, Keller S, Rupp C, et al.  Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol. 2007;107(3):563–571. doi: 10.1016/j.ygyno.2007.08.064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2007.08.064</ArticleId>
            <ArticleId IdType="pubmed">17900673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang B, Peng P, Chen S, et al.  Characterization and proteomic analysis of ovarian cancer-derived exosomes. J Proteomics. 2013;80:171–182. doi: 10.1016/j.jprot.2012.12.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jprot.2012.12.029</ArticleId>
            <ArticleId IdType="pubmed">23333927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei W, Li N, Sun Y, Li B, Xu L, Wu L. Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer. Oncotarget. 2017;8(14):23862–23870. doi: 10.18632/oncotarget.13317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.13317</ArticleId>
            <ArticleId IdType="pmc">PMC5410350</ArticleId>
            <ArticleId IdType="pubmed">27852043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anuradha S, Webb PM, Blomfield P, et al.  Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. Med J Aust. 2014;201(5):283–288. doi: 10.5694/mja14.00132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5694/mja14.00132</ArticleId>
            <ArticleId IdType="pubmed">25163381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget. 2017;8(13):21429–21443. doi: 10.18632/oncotarget.15249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.15249</ArticleId>
            <ArticleId IdType="pmc">PMC5400595</ArticleId>
            <ArticleId IdType="pubmed">28206954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang B, Yu L, Luo X, et al.  Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. Oncol Lett. 2017;14(1):217–223. doi: 10.3892/ol.2017.6111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2017.6111</ArticleId>
            <ArticleId IdType="pmc">PMC5494804</ArticleId>
            <ArticleId IdType="pubmed">28693156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang B, Yu L, Yang GZ, Luo X, Huang L. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2015;16(7):3003–3007. doi: 10.7314/apjcp.2015.16.7.3003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/apjcp.2015.16.7.3003</ArticleId>
            <ArticleId IdType="pubmed">25854397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y, Zhang X, Lin L, Ma XP, Ma YC, Liu PS. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev. 2014;15(3):1171–1176. doi: 10.7314/apjcp.2014.15.3.1171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/apjcp.2014.15.3.1171</ArticleId>
            <ArticleId IdType="pubmed">24606436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, Hu G, Yang Q, et al.  A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 2013;130(1):132–139. doi: 10.1016/j.ygyno.2013.04.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2013.04.048</ArticleId>
            <ArticleId IdType="pubmed">23623832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong R, Yu J, Pu H, Zhang Z, Xu X. Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer. J Int Med Res. 2012;40(2):681–686. doi: 10.1177/147323001204000231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/147323001204000231</ArticleId>
            <ArticleId IdType="pubmed">22613430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bondurant AE, Huang Z, Whitaker RS, Simel LR, Berchuck A, Murphy SK. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol. 2011;123(3):581–587. doi: 10.1016/j.ygyno.2011.08.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2011.08.029</ArticleId>
            <ArticleId IdType="pubmed">21955482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liggett TE, Melnikov A, Yi Q, et al.  Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011;120(1):113–120. doi: 10.1016/j.ygyno.2010.09.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2010.09.019</ArticleId>
            <ArticleId IdType="pmc">PMC3004216</ArticleId>
            <ArticleId IdType="pubmed">21056906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widschwendter M, Zikan M, Wahl B, et al.  The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. 2017;9(1):116. doi: 10.1186/s13073-017-0500-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13073-017-0500-7</ArticleId>
            <ArticleId IdType="pmc">PMC5740748</ArticleId>
            <ArticleId IdType="pubmed">29268796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forshew T, Murtaza M, Parkinson C, et al.  Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. doi: 10.1126/scitranslmed.3003726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3003726</ArticleId>
            <ArticleId IdType="pubmed">22649089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pereira E, Camacho-Vanegas O, Anand S, et al.  Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers. PLoS ONE. 2015;10(12):e0145754. doi: 10.1371/journal.pone.0145754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0145754</ArticleId>
            <ArticleId IdType="pmc">PMC4696808</ArticleId>
            <ArticleId IdType="pubmed">26717006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parkinson CA, Gale D, Piskorz AM, et al.  Exploratory Analysis of TP53 mutations in circulating tumour dna as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002198. doi: 10.1371/journal.pmed.1002198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1002198</ArticleId>
            <ArticleId IdType="pmc">PMC5172526</ArticleId>
            <ArticleId IdType="pubmed">27997533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du ZH, Bi FF, Wang L, Yang Q. Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer. Mol Genet Genomic Med. 2018;6(4):638–647. doi: 10.1002/mgg3.414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mgg3.414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanderstichele A, Busschaert P, Smeets D, et al.  Chromosomal instability in cell-free dna as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses. Clin Cancer Res. 2017;23(9):2223–2231. doi: 10.1158/1078-0432.CCR-16-1078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-1078</ArticleId>
            <ArticleId IdType="pubmed">27852697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen PA, Flowers N, Tong S, Hannan N, Pertile MD, Hui L. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening. BMC Med. 2016;14(1):126. doi: 10.1186/s12916-016-0667-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12916-016-0667-6</ArticleId>
            <ArticleId IdType="pmc">PMC4997750</ArticleId>
            <ArticleId IdType="pubmed">27558279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murtaza M, Dawson SJ, Tsui DWY, et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–112. doi: 10.1038/nature12065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12065</ArticleId>
            <ArticleId IdType="pubmed">23563269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thusgaard CF, Korsholm M, Koldby KM, Kruse TA, Thomassen M, Jochumsen KM. Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review. Gynecol Oncol. 2021;161(3):884–895. doi: 10.1016/j.ygyno.2021.04.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2021.04.020</ArticleId>
            <ArticleId IdType="pubmed">33892886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannopoulou L, Mastoraki S, Buderath P, et al.  ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. Gynecol Oncol. 2018;150(2):355–360. doi: 10.1016/j.ygyno.2018.05.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2018.05.026</ArticleId>
            <ArticleId IdType="pubmed">29807696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dvorská D, Braný D, Nagy B, et al.  Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples. Int J Mol Sci. 2019;20(17):E4119. doi: 10.3390/ijms20174119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20174119</ArticleId>
            <ArticleId IdType="pmc">PMC6747242</ArticleId>
            <ArticleId IdType="pubmed">31450846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer. 2009;124(2):387–393. doi: 10.1002/ijc.23957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.23957</ArticleId>
            <ArticleId IdType="pubmed">18942711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou F, Ma M, Tao G, et al.  Detection of circulating methylated opioid binding protein/cell adhesion molecule-like gene as a biomarker for ovarian carcinoma. Clin Lab. 2014;60(5):759–765. doi: 10.7754/clin.lab.2013.130446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7754/clin.lab.2013.130446</ArticleId>
            <ArticleId IdType="pubmed">24839818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SK S, Swamy SN, Premalatha CS, Pallavi VR, Gawari R. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma. Asian Pac J Cancer Prev. 2019;20(10):3001–3005. doi: 10.31557/APJCP.2019.20.10.3001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31557/APJCP.2019.20.10.3001</ArticleId>
            <ArticleId IdType="pmc">PMC6982682</ArticleId>
            <ArticleId IdType="pubmed">31653147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn. 2009;11(1):60–65. doi: 10.2353/jmoldx.2009.080072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/jmoldx.2009.080072</ArticleId>
            <ArticleId IdType="pmc">PMC2607567</ArticleId>
            <ArticleId IdType="pubmed">19074590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Gupta S, Badarukhiya JA, Sachan M. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer. Int J Cancer. 2020;147(6):1740–1752. doi: 10.1002/ijc.32984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32984</ArticleId>
            <ArticleId IdType="pubmed">32191343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen JD, Li L, Wang Y, et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–930. doi: 10.1126/science.aar3247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aar3247</ArticleId>
            <ArticleId IdType="pmc">PMC6080308</ArticleId>
            <ArticleId IdType="pubmed">29348365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>No JH, Kim K, Park KH, Kim YB. Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. Anticancer Res. 2012;32(8):3467–3471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22843932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhlmann JD, Schwarzenbach H, Wimberger P, Poetsch M, Kimmig R, Kasimir-Bauer S. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer. 2012;12:325. doi: 10.1186/1471-2407-12-325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-12-325</ArticleId>
            <ArticleId IdType="pmc">PMC3488536</ArticleId>
            <ArticleId IdType="pubmed">22849543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbosa A, Pinto P, Peixoto A, et al.  Next generation sequencing of tumor and matched plasma samples: identification of somatic variants in ctDNA from ovarian cancer patients. Front Oncol. 2021;11:754094. doi: 10.3389/fonc.2021.754094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2021.754094</ArticleId>
            <ArticleId IdType="pmc">PMC8515058</ArticleId>
            <ArticleId IdType="pubmed">34660321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Li H, Yu X, et al.  Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker. Cell Physiol Biochem. 2018;48(5):1983–1994. doi: 10.1159/000492521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000492521</ArticleId>
            <ArticleId IdType="pubmed">30092594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo YX, Neoh KH, Chang XH, et al.  Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer. Oncotarget. 2018;9(7):7522–7533. doi: 10.18632/oncotarget.23943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.23943</ArticleId>
            <ArticleId IdType="pmc">PMC5800921</ArticleId>
            <ArticleId IdType="pubmed">29484129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poveda A, Kaye SB, McCormack R, et al.  Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol. 2011;122(3):567–572. doi: 10.1016/j.ygyno.2011.05.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2011.05.028</ArticleId>
            <ArticleId IdType="pubmed">21664658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearl ML, Zhao Q, Yang J, et al.  Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. Gynecol Oncol. 2014;134(3):581–590. doi: 10.1016/j.ygyno.2014.06.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2014.06.013</ArticleId>
            <ArticleId IdType="pmc">PMC4160464</ArticleId>
            <ArticleId IdType="pubmed">24972191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearl ML, Dong H, Tulley S, et al.  Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs) Gynecol Oncol. 2015;137(2):229–238. doi: 10.1016/j.ygyno.2015.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2015.03.002</ArticleId>
            <ArticleId IdType="pmc">PMC5568621</ArticleId>
            <ArticleId IdType="pubmed">25769657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Ou X, Wu X. Proteomics profiling of plasma exosomes in epithelial ovarian cancer: a potential role in the coagulation cascade, diagnosis and prognosis. Int J Oncol. 2019;54(5):1719–1733. doi: 10.3892/ijo.2019.4742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2019.4742</ArticleId>
            <ArticleId IdType="pmc">PMC6438431</ArticleId>
            <ArticleId IdType="pubmed">30864689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwich E, Rebmann V, Horn PA, et al.  Vesicular-Bound HLA-G as a predictive marker for disease progression in epithelial ovarian cancer. Cancers (Basel) 2019;11(8):E1106. doi: 10.3390/cancers11081106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11081106</ArticleId>
            <ArticleId IdType="pmc">PMC6721594</ArticleId>
            <ArticleId IdType="pubmed">31382533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arend RC, Londoño AI, Montgomery AM, et al.  Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma. Mol Cancer Res. 2018;16(5):813–824. doi: 10.1158/1541-7786.MCR-17-0594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-17-0594</ArticleId>
            <ArticleId IdType="pmc">PMC6497146</ArticleId>
            <ArticleId IdType="pubmed">29523763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE, Choi EK. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. J Gynecol Oncol. 2019;30(3):e32. doi: 10.3802/jgo.2019.30.e32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3802/jgo.2019.30.e32</ArticleId>
            <ArticleId IdType="pmc">PMC6424844</ArticleId>
            <ArticleId IdType="pubmed">30887755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol. 2010;3(1):1–12. doi: 10.1593/tlo.09250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/tlo.09250</ArticleId>
            <ArticleId IdType="pmc">PMC2822448</ArticleId>
            <ArticleId IdType="pubmed">20165689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Della Pepa C, Tonini G, Santini D, et al.  Low Grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev. 2015;41(2):136–143. doi: 10.1016/j.ctrv.2014.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2014.12.003</ArticleId>
            <ArticleId IdType="pubmed">25573350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadlecki P, Antosik P, Grzanka D, Grabiec M, Walentowicz-Sadlecka M. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system. Tumour Biol. 2017;39(10):1010428317733984. doi: 10.1177/1010428317733984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1010428317733984</ArticleId>
            <ArticleId IdType="pubmed">28992761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu J, Wong F, Szymiczek A. Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer. Under review.</Citation>
        </Reference>
        <Reference>
          <Citation>Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(12):1147–1158. doi: 10.1080/14737140.2017.1398088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14737140.2017.1398088</ArticleId>
            <ArticleId IdType="pubmed">29086618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minato T, Ito S, Li B, et al.  Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125. Gynecol Oncol Rep. 2021;38:100847. doi: 10.1016/j.gore.2021.100847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gore.2021.100847</ArticleId>
            <ArticleId IdType="pmc">PMC8446792</ArticleId>
            <ArticleId IdType="pubmed">34557579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judson PL, Geller MA, Bliss RL, et al.  Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol. 2003;91(2):389–394. doi: 10.1016/j.ygyno.2003.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2003.08.004</ArticleId>
            <ArticleId IdType="pubmed">14599871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C, Lin X, He J, Liu N. Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis. Gynecol Oncol. 2021;161(2):613–620. doi: 10.1016/j.ygyno.2021.02.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2021.02.024</ArticleId>
            <ArticleId IdType="pubmed">33674144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolostova K, Matkowski R, Jędryka M, et al.  The added value of circulating tumor cells examination in ovarian cancer staging. Am J Cancer Res. 2015;5(11):3363–3375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4697683</ArticleId>
            <ArticleId IdType="pubmed">26807317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int J Gynecol Cancer. 2011;21(5):822–830. doi: 10.1097/IGC.0b013e318216cb91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/IGC.0b013e318216cb91</ArticleId>
            <ArticleId IdType="pubmed">21613958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chebouti I, Kuhlmann JD, Buderath P, et al.  ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer. Oncotarget. 2017;8(15):24303–24313. doi: 10.18632/oncotarget.13286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.13286</ArticleId>
            <ArticleId IdType="pmc">PMC5421848</ArticleId>
            <ArticleId IdType="pubmed">28388557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obermayr E, Bednarz-Knoll N, Orsetti B, et al.  Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget. 2017;8(63):106415–106428. doi: 10.18632/oncotarget.22468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.22468</ArticleId>
            <ArticleId IdType="pmc">PMC5739744</ArticleId>
            <ArticleId IdType="pubmed">29290959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuberi M, Mir R, Das J, et al.  Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clin Transl Oncol. 2015;17(10):779–787. doi: 10.1007/s12094-015-1303-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-015-1303-1</ArticleId>
            <ArticleId IdType="pubmed">26063644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halvorsen AR, Kristensen G, Embleton A, et al.  Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. Dis Markers. 2017;2017:3098542. doi: 10.1155/2017/3098542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/3098542</ArticleId>
            <ArticleId IdType="pmc">PMC5331307</ArticleId>
            <ArticleId IdType="pubmed">28293063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paracchini L, Beltrame L, Grassi T, Inglesi A, Fruscio R, Landoni F, Ippolito D, Delle Marchette M, Paderno M, Adorni M, Jaconi M, Romualdi C, D'Incalci M, Siravegna G, Marchini S. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer. Clin Cancer Res. 2021;27(9):2549–2559. doi: 10.1158/1078-0432.CCR-20-3345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-20-3345</ArticleId>
            <ArticleId IdType="pubmed">33323403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72(19):4875–4882. doi: 10.1158/0008-5472.CAN-12-2217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-2217</ArticleId>
            <ArticleId IdType="pmc">PMC3712191</ArticleId>
            <ArticleId IdType="pubmed">23002210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burrell RA, Swanton C. The evolution of the unstable cancer genome. Curr Opin Genet Dev. 2014;24:61–67. doi: 10.1016/j.gde.2013.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gde.2013.11.011</ArticleId>
            <ArticleId IdType="pubmed">24657538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–313. doi: 10.1038/nature10762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10762</ArticleId>
            <ArticleId IdType="pmc">PMC3367003</ArticleId>
            <ArticleId IdType="pubmed">22258609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27(8):1449–1455. doi: 10.1093/annonc/mdw142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw142</ArticleId>
            <ArticleId IdType="pubmed">27037296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan DSP, Kaye SB. Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: same or different? Am Soc Clin Oncol Educ Book. 2015;35(1):114–121. doi: 10.14694/EdBook_AM.2015.35.114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14694/EdBook_AM.2015.35.114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benner SE, Wahl GM, Von Hoff DD. Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs. 1991;2(1):11–25. doi: 10.1097/00001813-199102000-00002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00001813-199102000-00002</ArticleId>
            <ArticleId IdType="pubmed">1720337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patch AM, Christie EL, Etemadmoghadam D, et al.  Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–494. doi: 10.1038/nature14410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14410</ArticleId>
            <ArticleId IdType="pubmed">26017449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin KK, Harrell MI, Oza AM, et al.  BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210–219. doi: 10.1158/2159-8290.CD-18-0715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-18-0715</ArticleId>
            <ArticleId IdType="pubmed">30425037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017;35(12):1274–1280. doi: 10.1200/JCO.2016.70.4627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.70.4627</ArticleId>
            <ArticleId IdType="pubmed">28414925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weigelt B, Comino-Méndez I, de Bruijn I, et al.  Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res. 2017;23(21):6708–6720. doi: 10.1158/1078-0432.CCR-17-0544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-0544</ArticleId>
            <ArticleId IdType="pmc">PMC5728372</ArticleId>
            <ArticleId IdType="pubmed">28765325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10(13):4420–4426. doi: 10.1158/1078-0432.CCR-03-0732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-03-0732</ArticleId>
            <ArticleId IdType="pubmed">15240532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capizzi E, Gabusi E, Grigioni AD, De Iaco P, Rosati M, Zamagni C, et al.  Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. Diagn Mol Pathol. 2008;17(1):34–38. doi: 10.1097/PDM.0b013e3181359e1f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PDM.0b013e3181359e1f</ArticleId>
            <ArticleId IdType="pubmed">18303408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, et al.  Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010;116(8):1918–1925. doi: 10.1002/cncr.24997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.24997</ArticleId>
            <ArticleId IdType="pmc">PMC2854845</ArticleId>
            <ArticleId IdType="pubmed">20166213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. Int J Cancer. 2011;128(11):2572–2580. doi: 10.1002/ijc.25602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.25602</ArticleId>
            <ArticleId IdType="pubmed">20715113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choudhuri S, Sharma C, Banerjee A, Kumar S, Kumar L, Singh N. A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer. MolCellBiochem. 2014;386(1–2):25969. doi: 10.1007/s11010-013-1863-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11010-013-1863-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martignetti JA, Camacho-Vanegas O, Priedigkeit N, Camacho C, Pereira E, Lin L, et al.  Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia. 2014;16(1):97–103. doi: 10.1593/neo.131900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/neo.131900</ArticleId>
            <ArticleId IdType="pmc">PMC3924545</ArticleId>
            <ArticleId IdType="pubmed">24563622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, et al.  Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in patients with ovarian cancer. Clin Cancer Res. 2017;23(9):2213–2222. doi: 10.1158/1078-0432.ccr-16-1754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-16-1754</ArticleId>
            <ArticleId IdType="pubmed">27663594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratajska M, Koczkowska M, Zuk M, Gorczynski A, Kuzniacka A, Stukan M, et al.  Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer. Oncotarget. 2017;8(60):101325–32. doi: 10.18632/oncotarget.20722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.20722</ArticleId>
            <ArticleId IdType="pmc">PMC5731877</ArticleId>
            <ArticleId IdType="pubmed">29254167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morikawa A, Hayashi T, Shimizu N, Kobayashi M, Taniue K, Takahashi A, et al.  PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma. Oncotarget. 2018;9(20):15266–74. doi: 10.18632/oncotarget.24555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.24555</ArticleId>
            <ArticleId IdType="pmc">PMC5880602</ArticleId>
            <ArticleId IdType="pubmed">29632642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oikkonen J, Zhang K, Salminen L, et al.  Prospective Longitudinal ctDNA workflow reveals clinically actionable alterations in ovarian cancer. JCO Precis Oncol. 2019;3(1):12. doi: 10.1200/PO.18.00343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/PO.18.00343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwahashi N, Sakai K, Noguchi T, Yahata T, Matsukawa H, Toujima S, et al.  Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer personalized profiling by deep sequencing. Sci Rep. 2019;9(1):10426. doi: 10.1038/s41598-019-47030-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-47030-w</ArticleId>
            <ArticleId IdType="pmc">PMC6639322</ArticleId>
            <ArticleId IdType="pubmed">31320709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noguchi T, Sakai K, Iwahashi N, Matsuda K, Matsukawa H, Yahata T, et al.  Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer. Oncol Lett. 2020;19(4):2713–2720. doi: 10.3892/ol.2020.11356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2020.11356</ArticleId>
            <ArticleId IdType="pmc">PMC7068231</ArticleId>
            <ArticleId IdType="pubmed">32218822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han MR, Lee SH, Park JY, Hong H, Ho JY, Hur SY, et al.  Clinical implications of circulating tumor DNA from ascites and serial plasma in ovarian cancer. Cancer Res Treat. 2020;52(3):779–788. doi: 10.4143/crt.2019.700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4143/crt.2019.700</ArticleId>
            <ArticleId IdType="pmc">PMC7373868</ArticleId>
            <ArticleId IdType="pubmed">32106643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alves MC, Fonseca FLA, Yamada A, Barros L, Lopes A, Silva L, et al.  Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: a pilot study. Tumour Biol. 2020;42(5):1010428320919198. doi: 10.1177/1010428320919198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1010428320919198</ArticleId>
            <ArticleId IdType="pubmed">32364828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otsuka J, Okuda T, Sekizawa A, et al.  Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer. 2004;14(3):459–464. doi: 10.1111/j.1048-891x.2004.014305.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1048-891x.2004.014305.x</ArticleId>
            <ArticleId IdType="pubmed">15228418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vencken PMLH, Kriege M, Hoogwerf D, et al.  Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011;22(6):1346–1352. doi: 10.1093/annonc/mdq628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdq628</ArticleId>
            <ArticleId IdType="pubmed">21228333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Chan D, Ngan H. Mechanisms of chemoresistance in human ovarian cancer at a glance. Gynecology and Obstetrics. 2012;2(3):e104. 10.4172/2161-0932.1000e104.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu X, Gao Y, Lu Y, Zhang J, Li L. Oncogenes associated with drug resistance in ovarian cancer. J Cancer Res Clin Oncol. 2014;141:381–395. doi: 10.1007/s00432-014-1765-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-014-1765-5</ArticleId>
            <ArticleId IdType="pubmed">24997551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncol Rep. 2014;31:745–754. doi: 10.3892/or.2013.2910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2013.2910</ArticleId>
            <ArticleId IdType="pubmed">24337664</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
